Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ANL011
MIFTS: 41

Anal Canal Carcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Anal Canal Carcinoma

About this section

MalaCards integrated aliases for Anal Canal Carcinoma:

Name: Anal Canal Carcinoma 58 12 13 45 15
Anal Canal Cancer 12 15
Anal Canal and Perianal Gland Carcinoma 12
Cancer of the Anal Canal 38
Carcinoma of Anal Canal 74

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
anal canal carcinoma:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:0050688 DOID:6126
OMIM 58 105580
KEGG 38 H00044
MeSH 45 C563020
NCIt 51 C7489
ICD10 34 C21.1
MedGen 43 C0563211
SNOMED-CT via HPO 70 263681008
UMLS 74 C0563211
Sources

Summaries for Anal Canal Carcinoma

About this section
Disease Ontology : 12 An anal canal cancer that derives from epithelial cells.

MalaCards based summary : Anal Canal Carcinoma, also known as anal canal cancer, is related to anal carcinoma in situ and anal canal adenocarcinoma. An important gene associated with Anal Canal Carcinoma is ANC (Anal Canal Carcinoma), and among its related pathways/superpathways is Viral carcinogenesis. The drugs Fluorouracil and Ipilimumab have been mentioned in the context of this disorder. Affiliated tissues include prostate, liver and skin, and related phenotypes are anal canal squamous carcinoma and Reduced mammosphere formation

Description from OMIM: 105580
Sources

Related Diseases for Anal Canal Carcinoma

About this section

Diseases related to Anal Canal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Related Disease Score Top Affiliating Genes
1 anal carcinoma in situ 11.5
2 anal canal adenocarcinoma 11.3
3 anal canal squamous cell carcinoma 11.3
4 cervical intraepithelial neoplasia 10.1 CDKN2A NME1
5 inverted transitional papilloma 10.1 KRT7 CDKN2A
6 papilloma 10.1 CDKN2A KRT7
7 bladder carcinoma in situ 10.1 KRT7 CDKN2A
8 endocervical carcinoma 10.1 KRT7 CDKN2A
9 bile duct adenoma 10.1 KRT7 CDKN2A
10 adenoid basal cell carcinoma 10.1 KRT7 CDKN2A
11 vulval paget's disease 10.1 KRT7 CDKN2A
12 nasal cavity cancer 10.1 KRT7 CDKN2A
13 nasal cavity adenocarcinoma 10.1 KRT7 CDKN2A
14 vulvar disease 10.1 KRT7 CDKN2A
15 skin melanoma 10.1 CDKN2A NME1
16 vulva adenocarcinoma 10.1 KRT7 CDKN2A
17 glycogen-rich clear cell breast carcinoma 10.1 KRT7 CDKN2A
18 well-differentiated liposarcoma 10.1 KRT7 CDKN2A
19 mucinous bronchioloalveolar adenocarcinoma 10.1 KRT7 CDKN2A
20 laryngeal squamous cell carcinoma 10.1 CDKN2A NME1
21 nasal cavity squamous cell carcinoma 10.1 KRT7 CDKN2A
22 endocervical adenocarcinoma 10.0 KRT7 CDKN2A
23 cervical adenocarcinoma 10.0 CDKN2A KRT7
24 cervical adenosquamous carcinoma 10.0 KRT7 CDKN2A
25 basaloid squamous cell carcinoma 10.0 KRT7 CDKN2A
26 necrotizing sialometaplasia 10.0 KRT7 CDKN2A
27 adenocarcinoma in situ 10.0 KRT7 CDKN2A
28 tonsil cancer 10.0 KRT7 CDKN2A
29 vulva cancer 10.0 KRT7 CDKN2A
30 mucinous adenocarcinoma 10.0 KRT7 CDKN2A
31 pancreatic ductal carcinoma 10.0 CDKN2A KRT7
32 inverted papilloma 10.0 CDKN2A KRT7
33 hypopharynx cancer 10.0 NME1 CD6
34 pharynx cancer 10.0 CD6 CDKN2A
35 small cell carcinoma 10.0 CDKN2A KRT7
36 systemic lupus erythematosus 10.0
37 prostate cancer 10.0
38 prostate cancer, hereditary, 8 10.0
39 prostate cancer, hereditary, 6 10.0
40 squamous cell carcinoma 10.0
41 mammary paget's disease 10.0
42 lupus erythematosus 10.0
43 aplasia cutis congenita, nonsyndromic 10.0
44 suppression of tumorigenicity 12 10.0
45 leukemia 10.0
46 patulous eustachian tube 10.0
47 sex development disorder 10.0
48 adenocarcinoma 10.0
49 cell type benign neoplasm 10.0 CDKN2A KRT7
50 tongue disease 9.9 CDKN2A CD6

Graphical network of the top 20 diseases related to Anal Canal Carcinoma:



Diseases related to Anal Canal Carcinoma
Sources

Symptoms & Phenotypes for Anal Canal Carcinoma

About this section

Human phenotypes related to Anal Canal Carcinoma:

33
# Description HPO Frequency HPO Source Accession
1 anal canal squamous carcinoma 33 HP:0006763

Symptoms via clinical synopsis from OMIM:

58
Oncology:
anal canal squamous carcinoma

Clinical features from OMIM:

105580

GenomeRNAi Phenotypes related to Anal Canal Carcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 8.92 CD6 KRT7 NME1 RAN
Sources

Drugs & Therapeutics for Anal Canal Carcinoma

About this section

Drugs for Anal Canal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 40)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 2 51-21-8 3385
2
Ipilimumab Approved Phase 2,Phase 1 477202-00-9
3
nivolumab Approved Phase 2,Phase 1 946414-94-4
4
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
5
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
6
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
7
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
8
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
9
Edetic Acid Approved, Vet_approved Phase 2 60-00-4, 62-33-9 6049
10
Pentetic acid Approved Phase 2 67-43-6
11 Daratumumab Approved Phase 1, Phase 2 945721-28-8
12
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
13
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
14
Durvalumab Approved, Investigational Phase 2 1428935-60-7
15
Nimotuzumab Investigational Phase 2 780758-10-3, 828933-61-3
16 Mitoguazone Investigational Phase 2 459-86-9
17 Alkylating Agents Phase 2
18 Nucleic Acid Synthesis Inhibitors Phase 2
19 Antibiotics, Antitubercular Phase 2
20 Anti-Bacterial Agents Phase 2
21 Mitomycins Phase 2
22 Antibodies, Monoclonal Phase 2,Phase 1
23 Antibodies Phase 2,Phase 1
24 Antineoplastic Agents, Immunological Phase 2,Phase 1
25 Immunoglobulins Phase 2,Phase 1
26 Immunosuppressive Agents Phase 2
27 Antimetabolites Phase 2
28 Immunologic Factors Phase 2,Phase 1
29 Antimetabolites, Antineoplastic Phase 2
30 Antimitotic Agents Phase 2
31 taxane Phase 2
32 Vaccines Phase 2
33 Liver Extracts Phase 2
34 Albumin-Bound Paclitaxel Phase 2
35 Antineoplastic Agents, Phytogenic Phase 2
36 Angiogenesis Modulating Agents Phase 2
37 Angiogenesis Inhibitors Phase 2
38 Immunoglobulin G Phase 2
39 Adjuvants, Immunologic Phase 2
40 Interleukin-12 Phase 2

Interventional clinical trials:

(show all 23)
# Name Status NCT ID Phase Drugs
1 A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy Unknown status NCT00754078 Phase 2
2 Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life Recruiting NCT02701088 Phase 2 5Fluorouracile and Mitomycin-C
3 Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer Recruiting NCT02314169 Phase 2
4 Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers Terminated NCT01382745 Phase 2 Nimotuzumab
5 A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal. Completed NCT01941966 Phase 2 Capecitabine;Mitomycins
6 Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma Active, not recruiting NCT02402842 Phase 2 Docetaxel, Cisplatin and 5-Fluorouracil
7 Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal Terminated NCT01843452 Phase 2 MITOMYCIN;CAPECITABINE
8 A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy Recruiting NCT03597295 Phase 2 INCMGA00012
9 Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) Not yet recruiting NCT03946358 Phase 2 Atezolizumab;UCPVax
10 Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection Recruiting NCT02437851 Phase 2
11 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors Recruiting NCT02488759 Phase 1, Phase 2 Nivolumab;Ipilimumab;Relatlimab;Daratumumab
12 Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases Recruiting NCT02185443 Phase 2
13 Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers Recruiting NCT03403465 Phase 2
14 Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer Active, not recruiting NCT02560298 Phase 2 Capecitabine;Carboplatin;Cisplatin;Fluorouracil;Paclitaxel
15 DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Participants With Recurrent or Metastatic Human Papillomavirus Associated Cancers Recruiting NCT03439085 Phase 2
16 LET-IMPT and Standard Chemotherapy in Treating Patients With Newly Diagnosed Stage I-III Anal Canal Squamous Cell Cancer Recruiting NCT03690921 Phase 2 Cisplatin;Fluorouracil
17 Interstitial Brachytherapy Boost for Treatment of Anal Canal Cancers, Comparison of Two Dose Rates Completed NCT03465501
18 Medico-economic Evaluation Comparing Intensity-Modulated Radiation Therapy (IMRT) Performed by Helical Tomotherapy and Dynamic Arc Therapy in Prostate, Cervical and Anal Canal Cancers Active, not recruiting NCT01325961 Not Applicable
19 Immunomonitoring and Biomarker Research in Patients With Squamous Cell Anal Carcinoma Not yet recruiting NCT03942900
20 "Cross" Closure for Reconstructing the Perineal Wound of Abdominoperineal Resection Not yet recruiting NCT03731754 Not Applicable
21 Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal Recruiting NCT01845779 Not Applicable DCF regimen
22 Individual Following in Anal Cancer With PET/CT Recruiting NCT02697084
23 Chemoradiation and Endothelial Progenitor Cells in Colorectal Cancer Completed NCT00325871

Search NIH Clinical Center for Anal Canal Carcinoma

Cochrane evidence based reviews: anal canal carcinoma

Sources

Genetic Tests for Anal Canal Carcinoma

About this section
Sources

Anatomical Context for Anal Canal Carcinoma

About this section

MalaCards organs/tissues related to Anal Canal Carcinoma:

42
Prostate, Liver, Skin, Endothelial, Tongue, Breast, Tonsil
Sources

Publications for Anal Canal Carcinoma

About this section

Articles related to Anal Canal Carcinoma:

(show top 50) (show all 134)
# Title Authors Year
1
Long-term results of chemoradiation plus pulsed-dose-rate brachytherapy boost in anal canal carcinoma: A mono-institutional retrospective analysis. ( 30911306 )
2019
2
Role of pelvic chemoradiation therapy in patients with initially metastatic anal canal cancer: A National Cancer Data Base review. ( 30825391 )
2019
3
Prognostic significance of inflammatory-related parameters in patients with anal canal cancer. ( 30617412 )
2019
4
Association of Interim FDG-PET Imaging During Chemoradiation for Squamous Anal Canal Carcinoma With Recurrence. ( 29891206 )
2018
5
Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy. ( 30128811 )
2018
6
Prognostic factors of colostomy free survival in patients presenting with locally advanced anal canal carcinoma: A pooled analysis of two prospective trials (KANAL 2 and ACCORD 03). ( 30172453 )
2018
7
Synchronous anal canal carcinoma in a heterosexual couple. ( 30200930 )
2018
8
A Definitive IMRT-SIB with Concomitant Chemotherapy for Synchronous Locally Advanced Anal Canal Cancer and Prostate Cancer. ( 30034895 )
2018
9
Definitive chemoradiotherapy for anal canal cancer: single-center experience. ( 29992389 )
2018
10
Prognostic and Predictive Clinicopathologic Factors of Squamous Anal Canal Cancer in HIV-Positive and HIV-Negative Patients: Does HAART Influence Outcomes? ( 28948325 )
2018
11
Clinical and Economic Evaluation of Treatment Strategies for T1N0 Anal Canal Cancer. ( 27755059 )
2018
12
Proteomic signatures reveal a dualistic and clinically relevant classification of anal canal carcinoma. ( 27976366 )
2017
13
PET imaging in anal canal cancer: a systematic review and meta-analysis. ( 28972796 )
2017
14
Elevated risk of human papillomavirus-related second cancers in survivors of anal canal cancer. ( 28608917 )
2017
15
Predictors of Nonadherence to NCCN Guideline Recommendations for the Management of Stage I Anal Canal Cancer. ( 28275036 )
2017
16
Results of Surgical Salvage Treatment for Anal Canal Cancer: A Retrospective Analysis with Overview of the Literature. ( 28099957 )
2017
17
Epidemiology of Anal Canal Cancer. ( 27889039 )
2017
18
Diagnosis and Diagnostic Imaging of Anal Canal Cancer. ( 27889036 )
2017
19
Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer. ( 27503193 )
2017
20
Locally advanced anal canal carcinoma: is the addition of cetuximab the answer? ( 25976929 )
2016
21
Anal Canal Carcinoma in a Child With Disorders of Sex Development. ( 27037640 )
2016
22
Efficacy and safety of helical tomotherapy with daily image guidance in anal canal cancer patients. ( 27034083 )
2016
23
Shifting paradigm in the management of anal canal carcinoma. ( 25432583 )
2015
24
Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities. ( 25903798 )
2015
25
MITHRA - multiparametric MR/CT image adapted brachytherapy (MR/CT-IABT) in anal canal cancer: a feasibility study. ( 26622238 )
2015
26
Dose planning objectives in anal canal cancer IMRT: the TROG ANROTAT experience. ( 26229674 )
2015
27
Helical tomotherapy for the treatment of anal canal cancer: a dosimetric comparison with 3D conformal radiotherapy. ( 25908035 )
2015
28
Multiparametric MRI as an outcome predictor for anal canal cancer managed with chemoradiotherapy. ( 25885556 )
2015
29
Could concomitant radio-chemotherapy improve the outcomes of early-stage node negative anal canal cancer patients? A retrospective analysis of 122 patients. ( 25674700 )
2015
30
Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal cancer. ( 25424587 )
2015
31
Reply to phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. ( 24243421 )
2014
32
Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. ( 24243447 )
2014
33
Management of persistent anal canal carcinoma after combined-modality therapy: a clinical review. ( 24472223 )
2014
34
Retroperitoneoscopic Cutaneous Ureterostomy in the Supine Position to Relieve Painful Urinary-related Symptoms in an Advanced Anal Canal Cancer Patient. ( 26951955 )
2014
35
Saudi Oncology Society clinical management guideline series. Anal canal cancer 2014. ( 25491223 )
2014
36
Radiation therapy of anal canal cancer: from conformal therapy to volumetric modulated arc therapy. ( 25403766 )
2014
37
Interstitial high-dose rate brachytherapy as boost for anal canal cancer. ( 25377886 )
2014
38
External beam radiotherapy ± chemotherapy in the treatment of anal canal cancer: a single-institute long-term experience on 100 patients. ( 24766302 )
2014
39
Diagnostic performance of positron emission tomography/computed tomography using fluorine-18 fluorodeoxyglucose in detecting locoregional nodal involvement in patients with anal canal cancer: a systematic review and meta-analysis. ( 24672298 )
2014
40
Results of age-dependent anal canal cancer treatment: a single centre retrospective study. ( 24555918 )
2014
41
Changing patterns of anal canal carcinoma in the United States. ( 23509304 )
2013
42
Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. ( 23674135 )
2013
43
Benefit of MRI scanning in the pretreatment assessment of anal canal carcinoma. ( 24674573 )
2013
44
Sentinel node mapping in anal canal cancer: systematic review and meta-analysis. ( 24078990 )
2013
45
Radiochemotherapy and brachytherapy could be the standard treatment for anal canal cancer in elderly patients? A retrospective single-centre analysis. ( 23322520 )
2013
46
Light microscopic observation on phagocytosis of Candida spp. blastospores by Trichomonas vaginalis in a patient with anal canal carcinoma. ( 21395883 )
2012
47
Endobronchial metastases of anal canal carcinoma. ( 22055765 )
2012
48
Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. ( 22529257 )
2012
49
Chemotherapy in the treatment of anal canal carcinoma. ( 22658644 )
2012
50
Definitive organ-sparing treatment of anal canal cancer: can we afford to question it? ( 22278906 )
2012
Sources

Variations for Anal Canal Carcinoma

About this section
Sources

Expression for Anal Canal Carcinoma

About this section
Search GEO for disease gene expression data for Anal Canal Carcinoma.
Sources

Pathways for Anal Canal Carcinoma

About this section

Pathways related to Anal Canal Carcinoma according to KEGG:

38
# Name Kegg Source Accession
1 Viral carcinogenesis hsa05203
Sources

GO Terms for Anal Canal Carcinoma

About this section

Biological processes related to Anal Canal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.43 CDKN2A NME1 TENM1
2 hippocampus development GO:0021766 9.16 NME1 RAN
3 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 8.96 CD6 TENM1
4 DNA metabolic process GO:0006259 8.62 NME1 RAN
Sources

Sources for Anal Canal Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....